Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jan-Mar;21(1):18-24.
doi: 10.4103/0974-9233.124082.

Refractive surgery in systemic and autoimmune disease

Majed AlKharashi  1 , Kraig S Bower  1 , Walter J Stark  1 , Yassine J Daoud  1
Affiliations
Review

Refractive surgery in systemic and autoimmune disease

Majed AlKharashi et al. Middle East Afr J Ophthalmol. 2014 Jan-Mar.

Abstract

Patients with underlying systemic disease represent challenging treatment dilemma to the refractive surgeon. The refractive error in this patient population is accompanied by a systemic disease that may have an ocular or even a corneal component. The literature is rather sparse about the use of laser refractive surgery (LRS) and such procedure is not approved by the United States Food and Drug Administration (FDA) in this patient population. Patients with collagen vascular disease, diabetes mellitus (DM), allergic and atopic disease, or human immunodeficiency virus (HIV) are never ideal for LRS. Patients with uncontrolled systemic disease or ocular involvement of the disease should not undergo LRS. However, a patient with well-controlled and mild disease, no ocular involvement, and not on multidrug regimen may be a suitable candidate if they meet stringent criteria. There is a need for a large, multicenter, controlled trial to address the safety and efficacy of LRS in patients with systemic disease before such technology can be widely adopted by the refractive surgery community.

Keywords: Allergic and Atopic Disease; Collagen Vascular Disease; Diabetes Mellitus; HIV; Keloid; Laser Refractive Surgery; Pregnancy.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. O’Doherty M, O’Keeffe M, Kelleher C. Five year follow up of laser in situ keratomileusis for all levels of myopia. Br J Ophthalmol. 2006;90:20–3. - PMC - PubMed
    1. Hammond MD, Madigan WP, Jr, Bower KS. Refractive surgery in the United States Army, 2000-2003. Ophthalmology. 2005;112:184–90. - PubMed
    1. Solomon KD, Fernandez de Castro LE, Sandoval HP, Biber JM, Groat B, Neff KD, et al. Joint LASIK Study Task Force. LASIK world literature review: Quality of life and patient satisfaction. Ophthalmology. 2009;116:691–701. - PubMed
    1. FDA Labeling for Laser Refractive Surgery. [Last accessed on 2013 Jun 30]. Available from: http://www.fda.gov/MedicalDevices/Products and Medical Procedures/Surger... .
    1. American Academy of Ophthalmology Summary Recommendations for Keratorefractive Laser Surgery. 2013. Jun, [Last accessed on 2013 Aug 5]. Available from: http://one.aao.org/CE/Practice Guidelines/ClinicalStatements_Content.asp... .